Brief introduction of 197638-83-8

197638-83-8 1-Boc-4-(4-Formylphenyl)piperazine 2795509, apiperazines compound, is more and more widely used in various fields.

197638-83-8, 1-Boc-4-(4-Formylphenyl)piperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 20 terf-Butyl 4-(4-(6-bromo-7-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3H- imidazo[4,5-b]pyridin-2-yl)benzyl)piperazine-1-carboxylateTo a mixture of 5-bromo-4-(4-((5-methylisoxazol-3-yl)methyl)piperazin-1-yl)-3- nitropyridin-2-amine (prepared as described in example 74 of PCT/GB2006/004854; 0.039 g, 0.10 mmol) and EtOH (4.0 ml_) was added tert-butyl 4-(4- formylbenzyl)piperazine-1-carboxylate (0.040 g, 0.13 mmol) followed by a freshly prepared aqueous solution of Na2S2O4 (1M; 0.40 mL, 0.40 mmol). The reaction mixture was stirred at 80 0C for 20 h, then allowed to cool to room temperature and concentrated in vacuo. The residue was absorbed on silica gel, the free-running powder was placed on a 10 g isolute silica column, and elution with a gradient of methanol (0 to 6%) in ethyl acetate / dichloromethane (v:v; 1 :1 ) afforded the title compound as a pale yellow solid (0.031 g, 48%). 1H-NMR (500 MHz, DMSO-d6) 1.39 (s, 9H, OC(CH3)3), 2.40 (s, 3H, isoxazole-5-CH3), 2.34 (br t, J = 4.8 Hz, 4H), 2.64 (br s, 4H), 3.33 (br s, 4H), and 3.67 (br s, 4H) (4 x piperazine N(CH2)2), 3.56 (s, 2H) and 3.60 (s, 2H) (NCHs-isoxazole and C6H4CH2), 6.25 (s, 1H, isoxazole 4-H), 7.47 (d, J = 8.1 Hz, 2H) and 8.12 (d, J = 8.1 Hz, 2H) (3,5-C6H4 and 2,6-C6H4), 8.24 (s, 1 H, imidazo[4,5-/3]pyridine 5-H), 13.48 (br s, 1H, imidazo[4,5-fo]pyridine N-H);LC (Method B) – MS (ESI, m/z): Rt = 3.00 min – 651, 653 [(M+H) Br isotopic pattern]., 197638-83-8

197638-83-8 1-Boc-4-(4-Formylphenyl)piperazine 2795509, apiperazines compound, is more and more widely used in various fields.

Reference:
Patent; CHROMA THERAPEUTICS LTD.; WO2009/1021; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics